Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry

Withdrawn

• Conditions: Idiopathic Pulmonary Fibrosis

• Registration Number: NCT00212511
• Lead Sponsor: NYU Langone Health

Brief Summary

The purpose of this study is to create a database of demographics and samples in idiopathic pulmonary fibrosis.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-11
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-21
• Status Verified: 2017-04
• Last Update Submitted: 2017-04-26
• Last Update Posted: 2017-04-28
• Primary Completion: 2018-01
• Study Completion: 2018-01

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine cellular and molecular determinants of IPF	Long-Term	An IPF Registry is being established to assemble sufficient patients with IPF (especially in its earliest stage) for phase I therapeutic protocols. The Registry will incorporate demographic and clinical data for natural history studies; second, research data on physiology, high-resolution CT scan, questionnaires, and blood samples for blood banking to be collected every 6 months for prospective studies on pathophysiology; and third, response to standard therapies will be monitored to determine cellular and molecular relationships to clinical outcome and predictors of survival. This is done in order to better determine cellular and molecular determinants of IPF. This cohort will be large enough to commence a separate phase I protocol with molecular strategies of intervention.

Trial Locations

Locations (1)

NYU School of Medicine; 🇺🇸 New York, New York, United States